References
- Ethics__COVID-19__Restrictive_Measures_-_Apr_14.pdf. [cited 2022 Sep 1]; Available from: https://media.tghn.org/articles/Ethics__COVID-19__Restrictive_Measures_-_Apr_14.pdf.
- Zhang H, Han H, He T, et al. Clinical characteristics and outcomes of COVID-19–infected cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2021; 113(4):371–380. doi: 10.1093/jnci/djaa168.
- Zarifkar P, Kamath A, Robinson C, et al. Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis. Clin Oncol. 2021;33(3):e180–91–e191. doi: 10.1016/j.clon.2020.11.006.
- Uppdrag att löpande se över och vid behov uppdatera sammanställningen över de identifierade grupperna som löper störst risk att drabbas av särskilt allvarlig sjukdomsutveckling vid insjuknande i covid-19 (S2021/00825 delvis). [cited 2023 Feb 13]; Available from: https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/dokument-webb/ovrigt/socialstyrelsen-delredovisning-riskgrupper-covid-19.pdf.
- Förekomsten av antikroppar mot SARS-CoV-2 i Sverige, 26 April – 9 May 2021. [cited 2022 Sep 1]; Available from: https://www.folkhalsomyndigheten.se/contentassets/45eafde72689438a8a21efa93a5591a4/forekomsten-antikroppar-mot-sars-cov-2.pdf.
- Erdoğan AP, Ekinci F, Acar Ö, et al. Level of COVID-19 fear in cancer patients. Middle East Curr Psychiatry. 2022;29(1):9. doi: 10.1186/s43045-022-00181-5.
- Hoffman T, Kolstad L, Lindahl JF, et al. Diagnostic potential of a luminex-based coronavirus disease 2019 suspension immunoassay (COVID-19 SIA) for the detection of antibodies against SARS-CoV-2. Viruses. 2021;13(6):993. doi: 10.3390/v13060993.
- R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [Internet]. 2021. Available from: https://www.R-project.org/
- Carey LB, Cohen J, Koenig HG, et al. COVID-19, mental health and cancer. J Relig Health. [Internet]. 2021; Aug [cited 2022 Jun 2]60(4):2191–2195. Available from: https://link.springer.com/10.1007/s10943-021-01318-2 doi: 10.1007/s10943-021-01318-2.
- Moraliyage H, De Silva D, Ranasinghe W, et al. Cancer in lockdown: impact of the COVID-19 pandemic on patients with cancer. Oncologist. 2021;26(2):e342–4–e344. doi: 10.1002/onco.13604.
- Lee KA, Ma W, Sikavi DR, et al. Cancer and risk of COVID-19 through a general community survey. Oncologist. 2021;26(1):e182–5–e185.
- Rogiers A, Pires da Silva I, Tentori C, et al. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021;9(1):e001931. doi: 10.1136/jitc-2020-001931.
- Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919–1926. doi: 10.1016/S0140-6736(20)31173-9.
- Madan A, Siglin J, Khan A. Comprehensive review of implications of COVID‐19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic. Cancer Med. 2020;9(24):9205–9218. doi: 10.1002/cam4.3534.
- Brar G, Pinheiro LC, Shusterman M, et al. COVID-19 severity and outcomes in patients With cancer: a matched cohort study. J Clin Oncol. 2020;38(33):3914–3924. doi: 10.1200/JCO.20.01580.
- Yekedüz E, Utkan G, Ürün Y. A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19. Eur J Cancer. 2020;141:92–104. doi: 10.1016/j.ejca.2020.09.028.
- Chavez-MacGregor M, Lei X, Zhao H, et al. Evaluation of COVID-19 mortality and adverse outcomes in US patients With or Without cancer. JAMA Oncol. 2022;8(1):69–78. doi: 10.1001/jamaoncol.2021.5148.
- Ludvigsson JF. The first eight months of Sweden’s COVID‐19 strategy and the key actions and actors that were involved. Acta Paediatr. 2020; 109(12):2459–2471. doi: 10.1111/apa.15582.
- Baral S, Chandler R, Prieto RG, et al. Leveraging epidemiological principles to evaluate Sweden’s COVID-19 response. Ann Epidemiol. 2021;54:21–26.
- Patel NJ, D'Silva KM, Hsu TY-T, et al. Coronavirus disease 2019 outcomes among recipients of anti‐cd20 monoclonal antibodies for immune‐mediated diseases: a comparative cohort study. ACR Open Rheumatol. 2022;4(3):238–246. doi: 10.1002/acr2.11386.
- Liebers N, Speer C, Benning L, et al. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood. 2022;139(1):142–147. doi: 10.1182/blood.2021013445.
- Larfors G, Pahnke S, State M, et al. Covid-19 intensive care admissions and mortality among swedish patients with cancer. Acta Oncol. 2021; 60(1):32–34. doi: 10.1080/0284186X.2020.1854481.
- Ullgren H, Camuto A, Rosas S, et al. Clinical characteristics and factors associated with COVID-19-related death and morbidity among hospitalized patients with cancer: a Swedish cohort study. Acta Oncol. 2021; 60(11):1459–1465. doi: 10.1080/0284186X.2021.1958005.
- Pagano L. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. doi: 10.1186/s13045-021-01177-0.
- Ladoire S, Rederstorff E, Goussot V, et al. Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer Centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study. Eur J Cancer. 2022;165:13–24. doi: 10.1016/j.ejca.2022.01.005.
- Utrikesfödda och covid-19. Konstaterade fall, IVA-vård och avlidna bland utrikesfödda i Sverige. [cited 2022 Sep 1]. Available from: https://www.folkhalsomyndigheten.se/publikationer-och-material/publikationsarkiv/u/utrikesfodda-och-covid-19/.
- Sigorski D, Sobczuk P, Osmola M, et al. Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic therapy. ESMO Open. 2020;5(5):e000970. doi: 10.1136/esmoopen-2020-000970.